The clinical trial will include nearly 150 patients with advanced hepatocellular carcinoma that expresses glypican-3.

Bayer begins phase I study targeting GPC3 with actinium-225 radiopharmaceutical in patients with advanced hepatocellular carcinoma: Berlin Wednesday, April 30, 2025, 12:00 Hrs [IS ...

Bayer has launched a first-in-human clinical trial for 225Ac-GPC3 (BAY 3547926), a novel targeted alpha radiopharmaceutical ...

Bayer announced today initiation of a Phase I clinical trial with 225Ac-GPC3 (BAY 3547926), an investigational targeted alpha radiopharmaceutical being developed to treat tumors expressing Glypican-3 ...

The USFDA conducted a surveillance inspection at the group's API Unit, located at Dabhasa in Gujarat. The inspection was ...

ITM Isotope Technologies Munich, Alpha-9 Oncology sign supply agreement for therapeutic medical radioisotope Actinium-225: Munich, Germany Saturday, April 26, 2025, 10:00 Hrs [IST ...

Garching / Munich, Germany and VANCOUVER, British Columbia, April 24, 2025 – ITM Isotope Technologies Munich SE (ITM), a ...

Modern medicine is experiencing a period of significant advancements and innovations, and at its core is radiopharmaceuticals ...

A breakthrough in cancer treatment may soon change how some of the most aggressive tumors are managed. A small, ...

Jeffrey Wong, MD, discusses the evolving field of combination therapy with radiopharmaceuticals in prostate cancer.

Quick advancements in cancer treatment are crucial as traditional therapies face challenges of limited specificity and ...